Identification of enzymes responsible for rifalazil metabolism in human liver microsomes

Xenobiotica

Volumn 30, Issue 6, 2000, Pages 565-574

  Mae, T ^a   Inaba, T ^b   Konishi, E ^a   Hosoe, K ^a   Hidaka, T ^a  

^a KANEKA CORPORATION   (Japan)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 CHLOROMERCURIBENZOIC ACID; 4 NITROPHENYL PHOSPHATE; 5,5' DITHIOBIS(2 NITROBENZOIC ACID); ASTEMIZOLE; AZITHROMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DYFLOS; ESTERASE; ESTERASE INHIBITOR; FLUCONAZOLE; KETOCONAZOLE; LORATADINE; MICONAZOLE; MIDAZOLAM; NEOSTIGMINE; NIFEDIPINE; PHYSOSTIGMINE; RIFALAZIL; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DEACYLATION; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG METABOLISM; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CYTOSOL; LIVER MICROSOME METABOLISM; STRUCTURE ANALYSIS;

EID: 0033922469     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982500406408     Document Type: Article

References (34)

1. ALDRIDGE, W. N., 1953, Serum esterases: two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination. Biochemical Journal, 53, 110-117.
2. 14C-rifabutin in animals and man. Journal of Antimicrobial Chemotherapy, 26, 813-822.
3. BERMUDEZ, L. E., KOLONOSKI, P., YOUNG, L. S. and INDERLIED, C. B., 1994, Activity of KRM-1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection. Antimicrobial Agents and Chemotherapys, 38, 1844-1848.
4. COCCHIARA, G., STROLIN BENEDETTI, M., VICARIO, G. P., BALLABIO, M., GIOIA, B., VIOGLIO, S. and VIGEVANI, A., 1989, Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers. Xenobiotica, 19, 769-780.
5. FUJH, K., TSUJI, A., MIYAZAKI, S., YAMAGUCHI, K. and GOTO, S., 1994, In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. Antimicrobial Agents and Chemotherapy, 38, 1118-1122.
6. HIRATA, T., SAITO, H., TOMIOKA, H., SATO, K., JIDOI, J., HOSOE, K. and HIDATA, T., 1995, In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 39, 2295-2303.
7. HOSOE, K., MAE, T., KONISHI, E., FUJH, K., YAMASHITA, K., YAMANE, T., HIDAKA, T. and OHASI, T., 1996a, Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs. Antimicrobial Agents and Chemotherapy, 40, 2749-2755.
8. HOSOE, K., MAE, T., YAMASHITA, K., FUJH, K., YAMANE, T., HIDAKA, T. and OHASI, T., 1996b, Identification and antimicrobial activity of urinary metabolites of a rifamycin derivative in dog. Xenobiotica, 26, 321-332.
9. IATSIMIRSKAIA, E., TULEBAEV, S., STOROZHUK, E., UTKIN, I., SMITH, D., GERBER, N. and KOUDRIAKOVA, T., 1997, Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clinical Pharmacology and Therapeutics, 61, 554-562.
10. INABA, T., FISCHER, N. E., RIDDICK, D. S., STEWART, D. J. and HIDAKA, T., 1997, HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. Toxicology Letters, 93, 215-219.
11. INDERLIED, C. B., BARBARA-BURNHAM, L., WU, M., YOUNG, L. and BERMUDEZ, L. E., 1994, Activity of the benzoxazinorifamycin KRM-1648 against the Mycobacterium avium complex in vitro and in macrophages. Antimicrobial Agents and Chemotherapy, 38, 1838-1843.
12. JAMIS-DOW, C. A., KATKI, A. G., COLLINS, J. M. and KLECKER, R. W., 1997, Rifampicin and rifabutin and their metabolism by human liver esterases. Xenobiotica, 27, 1015-1024.
13. KELLY, B. P., FURNEY, S. K., JESSEN, M. T. and ORME, I. M., 1996, Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 40, 2809-2812.
14. KLEMENS, S. P., GROSSI, M. A. and CYNAMON, M. H., 1994, Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrobial Agents and Chemotherapy, 38, 2245-2248.
15. LUNA-HERRERA, J., REDDY, M. V. and GANGADHARAM, P. R. J., 1995, In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrobial Agents and Chemotherapy, 39, 440-444.
16. MAE, T., HOSOE, K., FUJH, K., YAMASHITA, K., YAMANE, T., HIDAKA, T. and OHASHI, T., 1996, In vitro metabolism of a rifamycin derivative by animal and human liver microsomes, whole blood and expressed human CYP3A isoform. Xenobiotica, 26, 793-802.
17. MAE, T., HOSOE, K., YAMAMOTO, T., HIDAKA, T., OHASHI, T., KLEEMAN, J. M. and ADAMS, P. E., 1998, Effect of a new rifamycin derivative, rifalazil, on liver microsomal enzyme induction in rat and dog. Xenobiotica, 28, 759-766.
18. MAE, T., KONISHI, E., HOSOE, K. and HIDAKA, T., 1999, Isolation and identification of major metabolites of rifalazil in mouse and human. Xenobiotica, 29, 1073-1087.
19. MOGHAZEH, S. L., PAN, X., ARAIN, T., STOVER, C. K., MUSSER, J. M. and KREISWIRTH, B. N., 1996, Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrobial Agents and Chemotherapy, 40, 2655-2657.
20. MOR, N., SIMON, B. and HEIFETS, L., 1996, Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages. Antimicrobial Agents and Chemotherapy, 40, 1482-1485.
21. PARKINSON, A., 1996, Biotransformation of xenobiotics. In C. D. Klaassen (eds), Casaret & Doull's Toxicology: The Basic Science of Poisons, 5th edn (New York: McGraw-Hill), pp. 113-186.
22. REDDY, M. V., LUNA-HERRERA, J., DANELUZZI, D. and GANGADHARAM, P. R., 1996, Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice. Tubercle and Lung Disease, 77, 154-159.
23. 14C-rifapentine in healthy volunteers. Drug Metabolism and Disposition, 26, 732-738.
24. SAITO, H., TOMIOKA, H., SATO, K., EMORI, M., YAMANE, T., YAMASHITA, K., HOSOE, K. and HIDAKA, T., 1991, In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrobial Agents and Chemotherapy, 35, 542-547.
25. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
26. SUMIDA, A., KINOSHITA, K., FUKUDA, T., MATSUDA, H., YAMAMOTO, I., INABA, T. and AZUMA, J., 1999, Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver. Biochemical and Biophysical Research Communications, 262, 499-503.
27. TOMIOKA, H., SAITO, H., FUJH, K., SATO, K. and HIDAKA, T., 1993, In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex determined by the radiometric method. Antimicrobial Agents and Chemotherapy, 37, 67-70.
28. TOMIOKA, H., SAITO, H., SATO, K., YAMANE, T., YAMASHITA, K., HOSOE, K., FUJH, K. and HIDAKA, T., 1992, Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrobial Agents and Chemotherapy, 36, 387-393.
29. TRAPNELL, C. B., JAMIS-DOW, C., KLECKER, R. W. and COLLINS, J. M., 1997, Metabolism rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole. Antimicrobial Agents and Chemotherapy, 41, 924-926.
30. UTKIN, I., KOUDRIAKOVA, T., THOMPSON, T., COTTRELL, C., IATSIMIRSKAIA, E., BARRY, J., VOUROS, P. and GERBER, N., 1997, Isolation and identification of major urinary metabolites of rifabutin in rats and humans. Drug Metabolism and Disposition, 25, 963-969.
31. VIGEVANI, A., BALLABIO, M., GIOIA, B., MARSILI, L., VIOGLIO, S. and FRANCESCHI, G., 1985, Identification of urinary metabolites of rifamycin LM 427 in man. Journal of Antibiotics, 38, 1799-1802.
32. WILLIAMS, F. M., 1985, Clinical significance of esterases in man. Clinical Pharmacokinetics, 10, 392-403.
33. YAMANE, T., HASHIZUME, T., YAMASHITA, K., KONISHI, E., HOSOE, K., HIDATA, T., WATANABE, K., KAWAHARADA, H., YAMAMOTO, T. and KUZE, F., 1993, Synthesis and biological activity of 3′-hydroxy-5′-aminobenzoxazinorifamycin derivatives. Chemical and Pharmaceutical Bulletin, 41, 148-155.
34. YANG, B., KOGA, H., OHNO, H., OGAWA, K., FUKUDA, M., HIRAKATA, Y., MAESAKI, S., TOMONO, K., TASHIRO, T. and KOHNO, S., 1998, Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 42, 621-628.